STZ treatment also upregulated long‐chain acyl‐CoA synthetase 4 (ACSL4),[36] promoting the accumulation of polyunsaturated fatty acids, such as arachidonic acid, further contributing to dyslipidemia. The gene discussed is ACSL4; the disease is metabolic syndrome.